Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PF Form 4 July 18, 2011	IARMACEUT	TICALS INC	C/MA								
									OMB AF	PPROVAL	
CURIVI 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									OMB Number:	3235-0287	
Check thi if no long subject to Section 1 Form 4 o Form 5	s box ger STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF 6. SECURITIES								Expires: January 31 Expires: 2009 Estimated average burden hours per response 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type F	Responses)										
MUELLER PETER Symt				Name and X PHAR	MACEU			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O VERTE PHARMAC INCORPOR ST		(Middle)		Earliest Tr ay/Year)	-			Director X Officer (give below) EVP, G		o Owner er (specify SO	
				ndment, Date Original nth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
(City)	(State)	(Zip)						Person			
	````							uired, Disposed of			
1.Title of Security       2. Transaction Date       2A. Deemed         (Month/Day/Year)       Execution Date, if any (Month/Day/Year)		n Date, if	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
Common				Code V	Amount	(D)	Price \$				
Stock	07/15/2011			М	2,500	А	ф 10.41	136,235	D		
Common Stock	07/15/2011			S <u>(1)</u>	2,500	D	\$ 50.68 (2) (3)	133,735	D		
Common Stock								4,495	Ι	401(k)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exerc	cisable and	7. Title and A	Amount of	8. I
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction of Derivative		Expiration Date		Underlying Securities		Der
Security	or Exercise		any	Code Securities		(Month/Day/Year)		(Instr. 3 and 4)		Sec
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired	•				(In
. ,	Derivative		· · · ·	, ,	(A) or					
	Security				Disposed of					
	Security				(D)					
					(Instr. 3, 4,					
					(1130, 3, 4) and 5)					
					and <i>S</i> )					
									Amount	
						D (	т ·		or	
						Date	Expiration	Title	Number	
						Exercisable	Date		of	
				Code V	(A) (D)				Shares	
Stock Options	\$ 10.41	07/15/2011		М	2,500	(4)	02/02/2015	Common Stock	2,500	

## **Reporting Owners**

Reporting Owner Name / Address		Relationships				
r o o o o o o o			10% Owner	Officer	Other	
MUELLER PETER C/O VERTEX PHARMACEUTICALS 130 WAVERLY ST CAMBRIDGE, MA 02139	INCORPORATED			EVP, Global R&D, CSO		
Signatures						
Kenneth S. Boger, Attorney-In-Fact	07/18/2011					

**Signature of Reporting Person

Date

# **Explanation of Responses:**

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$50.68 (range \$50.29 to \$51.12).
- (3) Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.